Animal model of brain tumor and manufacturing method of animal model

Patent metadata

Field	Value
Publication number	US-2023232794-A1
Application number	US-202217956771-A
Country	US
Kind code	A1
Filing date	Sep 29, 2022
Priority date	Feb 6, 2018
Publication date	Jul 27, 2023
Grant date	—

Abstract

The present invention relates to a brain tumor animal model that directly reflects the phenomenon in a human patient and a method of preparing the same, and more specifically, a brain tumor animal model that mutations are introduced into p53, Pten, and EGFR genes, a screening method of a therapeutic agent for a brain tumor using the animal model, and a preparing method thereof.

First claim

1 . A non-human transgenic animal comprising,
knock-out mutations of p53 and Pten genes in neural stem cells of subventricular zone (SVZ), and an activating mutation of epidermal growth factor receptor (EGFR) gene in neural stem cells of SVZ, wherein the animal has glioblastoma in the dorsolateral-caudal cortex region.

2 . The non-human animal of claim 1 , wherein the neural stem cells of SVZ are positive for Glial fibrillary acidic protein (GFAP).

3 . The non-human animal of claim 2 , wherein the GFAP-positive neural stem cells of SVZ have normal cytoarchitecture.

4 . The non-human animal of claim 1 , wherein the glioblastoma develops from neural stem cells that are positive for Glial fibrillary acidic protein (GFAP),

5 . The non-human animal of claim 1 , wherein the animal is rodent.

6 . The non-human transgenic animal of claim 1 , wherein the glioblastoma is a high-grade glioblastoma having characteristics of necrosis, microvascular proliferation and mitosis, and has an immune response to GFAP, Nestin, Olig2, and PDGFRα.

7 . The non-human transgenic animal of claim 1 , wherein the glioblastoma is IDH-wild type.

8 . The non-human transgenic animal of claim 1 , wherein the animal maintains the knockout mutations of p53 and Pten genes specific to neural stem cells in SVZ even after glioblastoma occurrence.

9 . The non-human transgenic mouse of claim 1 , wherein the p53 gene comprises at least a nucleotide sequence of SEQ. ID NOs. 38 to 40, and the Pten gene comprises at least a nucleotide sequence of SEQ. ID NOs. 41 to 43.

Assignees

• Korea Advanced Inst Sci & Tech
• Yonsei Univ Univ Industry Foundation Uif

Inventors

• Kang Seok Gu
• Lee Jeong Ho
• Lee Joo Ho
• Lee Jeong Eun

Classifications

• C07K14/4748

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title

• C07K14/4702

  Regulators; Modulating activity · CPC title

• C07K14/71

  for growth factors; for growth regulators · CPC title

• C12N9/16

  acting on ester bonds (3.1) · CPC title

• C12Y301/03067

  Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67) · CPC title